



**Prof. Paul Mulder (Partner 1 and French coordinator)** is a cardiovascular physiologist with more than 35 years of expertise in experimental pharmacology, with a focus on cardiometabolic research (i.e. heart failure, hypertension, and metabolic syndrome). After completing his pharmacy study, he obtained his PhD in 1991 in Paris and then moved to Rouen in France. There he is responsible for assessments of systemic and cardiac hemodynamics, cardiovascular functions in rat models of hypertension, heart failure, acute decompensation at INSERM U1096, and his expertise is recognized by ample collaborations with national and international pharmaceutical companies (i.e. Servier, Sanofi, Poxel, CorteriaPharma, Bayer, Novartis, Idorsia, Boehringer-Ingelheim). He is involved in two on-going EU projects: a Marie Skłodowska–Curie project as a partner, and an

ERA4Health program project 'Research targeting development of innovative therapeutic strategies in cardiovascular disease, CARDINNOV' as the project coordinator.

**Mulder P**, Richard V, Derumeaux G, Hogie M, Henry JP, Lallemand F, Compagnon P, Mace B, Comoy E, Letac B, Thuillez C. Role of endogenous endothelin in chronic heart failure: effect of a long term treatment with an endothelin antagonist on survival, hemodynamics and cardiac remodeling. *Circulation* 1997;96:1976-1982.

**Mulder P**, Barbier S, Chagraoui A, Richard V, Henry J-P, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. *Circulation* 2004;109:1674-1679.

Merabet N, Bellien J, Glevarec E, Nicol L, Lucas D, Jouet D, Bounoure F, Dreano Y, Wecker D, Thuillez C, **Mulder P**. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure *J Mol Cell Cardiol.* 2012;52(3):660-6.

Henri O, Poueche C, Galas L, Houssari M, Nicol L, Edwards-Lévy F, Henry J-P, Dumesnil A, Banquet S, Schapman D, Thuillez C, Richard V, **Mulder P**, Brakenhielm E. Selective stimulation of cardiac lymphangiogenesis reduces myocardial edema and fibrosis leading to improved cardiac function following myocardial infarction. *Circulation* 2016 ; 133: 1484-97.

Harouki N, Nicol L, Remy-Jouet I, Henry JP, Dusmenil A, Lejeunne A, Renet S, Golding F, Djerada Z, Wecker D, Bolduc V, Bouly M, Roussel J, Richard V, **Mulder P**. The IL-1 $\beta$  antibody gevokizumab limits cardiac remodeling and coronary dysfunction in rats with heart failure. *JACC: Basic to Translational Science. J Am Coll Cardiol Basic Trans Science* 2017;2:418–30.

Peschanski N, Harouki N, Soulie M, Lachaux M, Nicol L, Remy-Jouet L, Henry JP, Dumesnil A, Renet S, Fougousse F, Brakenhielm E, Ouvrard-Pascaud A, Thuillez C, Richard V, Roussel J, **Mulder P**. Transient heart rate reduction improves acute decompensated heart failure-induced left ventricular and coronary Dysfunction. *ESC Heart Failure* 2020. DOI: 10.1002/ehf2.13094.